Policy Watch: FDA, DEA and Ad Rules for Peptide, GLP-1 and TRT Clinics
Last verified: October 30, 2026 · By Ernesto Cullari, Ernesto Cullari Media LLC. An operator's guide, not legal or medical advice.
Quick answer
Three dated items matter most for a US telehealth clinic selling TRT, peptide or GLP-1 programs as of October 30, 2026. DEA and HHS extended the telemedicine flexibilities for prescribing controlled medications through December 31, 2026, and a Federal Register search found no final replacement rule. FDA proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list, and a search found no final determination. FDA's March 2026 warning letters to 30 telehealth companies targeted claims that compounded GLP-1 products match approved drugs.
This page tracks dated changes that affect US telehealth clinics selling TRT, HRT, peptide and GLP-1 programs. Every entry links to its primary source: the Federal Register, FDA, or a platform's own policy page. The "What to check" lines are prompts to take to your counsel. New entries go at the top, and old entries stay with their dates.
DEA telemedicine flexibilities end December 31, 2026
Status: in effect through December 31, 2026.
DEA and HHS issued a fourth temporary extension of the telemedicine flexibilities for prescribing controlled medications. It was published December 31, 2025 (90 FR 61301), took effect January 1, 2026 and runs through December 31, 2026.
The Ryan Haight Act generally requires that the prescriber, or a covering practitioner, has conducted at least one in-person medical evaluation of the patient before a controlled substance is prescribed by means of the internet, unless an exception applies (21 U.S.C. § 829(e)). The temporary extensions are one such exception. Ask your counsel whether any other exception covers your practice.
DEA has not published a final rule replacing the extensions. A Federal Register search on October 30, 2026 for DEA documents on telemedicine and special registration published after January 2, 2026 returned no results.
What to check:
Which of your products are controlled substances. Testosterone is listed in Schedule III (21 CFR 1308.13).
What happens to existing patients and refills on January 1, 2027 if nothing replaces the extension, and whether your state adds its own in-person requirement.
Whether your plan works under both outcomes. The flexibilities have been extended four times, and none of the extensions is permanent.
FDA proposes to leave semaglutide, tirzepatide and liraglutide off the 503B bulks list
Status: proposed. No final determination found.
FDA announced the proposal on April 30, 2026, and the notice was published May 1, 2026 (91 FR 23431). FDA proposes that there is no clinical need for outsourcing facilities to compound these three drugs from bulk substances. On June 26, 2026, FDA extended the comment period by 30 days, to July 30, 2026 (91 FR 38719).
A Federal Register search on October 30, 2026 for documents published after July 1, 2026 on the 503B bulk drug substances list found two notices, both unrelated to these drugs, and no final determination.
The proposal concerns 503B outsourcing facilities. Whether a 503A pharmacy can still compound these drugs for individual patients is a separate question.
What to check:
Ask each pharmacy partner in writing whether your GLP-1 supply comes from a 503A pharmacy or a 503B outsourcing facility.
Write your supply plan for both outcomes of the final decision.
FDA warns 30 telehealth companies over compounded GLP-1 marketing
Status: past action (March 3, 2026). Enforcement continues.
FDA issued 30 warning letters to telehealth companies over website claims about compounded GLP-1 products. The announcement names two problems. One is implying that a compounded product is equivalent to an FDA-approved one. The other is marketing compounded drugs under the telehealth company's own name or trademark without making clear who compounds them. FDA notes that compounded drugs are not FDA-approved, so the agency does not review them for safety, effectiveness or quality.
What to check:
Search your site, ads and emails for "same as," "generic" and the brand names of approved drugs.
Check that each product page says who compounds the product.
Status: past action (March 31, 2026, and later). Letters continue.
FDA's March 31, 2026 letter to Gram Peptides treats retatrutide and tirzepatide as unapproved new drugs because the company's website markets them for weight loss and glucose control. The company labeled its products "Research Use Only" and "not intended for human consumption." The letter says its marketing shows the products are meant for human use, so the disclaimers do not change the result. FDA asked for a written response within 15 working days.
Checked and not applicable: Google Ads Healthcare and Medicines updates
Status: no US change found in these two updates.
Google announced updates to its Healthcare and Medicines policy on April 7, 2026 and on July 22, 2026. The April update changes the rules for India, where certified online pharmacies can promote prescription drug services (April 2026). The July update changes the rules for Spain, where certified telemedicine providers can advertise prescription drug services (July 2026). Neither page mentions compounded drugs or the United States. I did not review other Google policy changes in this edition. For US rules, see Google, Meta and TikTok ad rules for peptide and GLP-1 clinics, last verified October 4, 2026.
When the next edition publishes
The next scheduled edition is the first week of December 2026, ahead of the DEA deadline. It publishes sooner if DEA, FDA or an ad platform issues a change. This edition does not review Meta or TikTok policy pages.
Legal disclaimer: This article is for informational purposes only and is not legal, regulatory, medical or compliance advice. Rules, enforcement and platform policies change. Consult qualified legal counsel before you act on anything here.
Run a Prescriber-Led Clinic on One Platform
LUKE is a telehealth platform, built HIPAA-first, for clinics offering TRT, HRT, peptide therapy and GLP-1 weight management. Clinical workflows and a lead CRM share one system.
When do the DEA telemedicine flexibilities for controlled substances end?
They run through December 31, 2026 under the fourth temporary extension (90 FR 61301). As of October 30, 2026, a Federal Register search found no DEA final rule on telemedicine special registration published after January 2, 2026.
Has FDA decided whether compounded semaglutide and tirzepatide can go on the 503B bulks list?
Not as of October 30, 2026. FDA proposed on April 30, 2026 to leave semaglutide, tirzepatide and liraglutide off the list, and extended comments to July 30, 2026. A Federal Register search found no final determination.
What did FDA's March 2026 letters to telehealth companies target?
Marketing that implies compounded GLP-1 products are equivalent to FDA-approved drugs, and marketing compounded drugs under the telehealth company's own name or trademark without making clear who compounds them.
Does a Research Use Only label protect a peptide seller?
No. FDA's March 31, 2026 letter to Gram Peptides rejected the company's research-use disclaimers because its marketing showed the products were meant for human use.